|
業務類別
|
Biotechnology |
|
業務概覽
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
| 公司地址
| Baarerstrasse 14, Zug, CHE, 6300 |
| 電話號碼
| +41 415613277 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.crisprtx.com |
| 員工數量
| 393 |
| Mr. Naimish Patel, M.D. |
Chief Medical Officer |
美元 551.05K |
21/04/2026 |
| Mr. James R. Kasinger |
General Counsel and Secretary |
美元 494.17K |
21/04/2026 |
| Dr. Samarth Kulkarni, PhD |
Chairman of the Board and Chief Executive Officer |
美元 768.62K |
21/04/2026 |
| Dr. Raju Prasad |
Chief Financial Officer and Principal Accounting Officer |
美元 493.51K |
21/04/2026 |
|
|
| Dr. Simeon J. George, M.B.A.,M.D. |
Independent Director |
21/04/2026 |
| Mr. Sandesh Mahatme, L.L.M. |
Independent Director |
21/04/2026 |
| Dr. Briggs W. Morrison, M.D. |
Independent Director |
21/04/2026 |
| Dr. Katherine A. High, M.D. |
Independent Director |
21/04/2026 |
| Dr. H. Edward Fleming, Jr,M.D. |
Independent Director |
21/04/2026 |
| Dr. Christian Rommel, PhD |
Independent Director |
21/04/2026 |
| Dr. Douglas A. Treco, PhD |
Lead Independent Director |
21/04/2026 |
| Dr. Samarth Kulkarni, PhD |
Chairman of the Board and Chief Executive Officer |
21/04/2026 |
| Dr. Ali Behbahani, M.B.A.,M.D. |
Independent Director |
21/04/2026 |
| Mr. John T. Greene |
Independent Director |
21/04/2026 |
| Dr. Maria Fardis, PhD |
Independent Director |
21/04/2026 |
|
|
|
|
